Skip to content

The effect of phoenix Dactylifera supplementary on fatigue in patients with multiple sclerosis

The effect of phoenix Dactylifera supplementary on fatigue in patients with multiple sclerosis

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20230706058689N1
Enrollment
50
Registered
2023-12-29
Start date
2023-12-30
Completion date
Unknown
Last updated
2024-01-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple sclerosis. Multiple sclerosis

Interventions

Intervention 1: Intervention group: phoenix dactylifera (Date Palm pollen), 300 mg capsules, twice a day at 10 am and 10 pm, place of production: Tehran Faculty of Pharmacy, Medical Sciences. Interven

Sponsors

Arak University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Having a history of MS for at least 3 months (based on the information in the patient's file) Age 18 to 60 years Absence of food and drug allergy (date products) Obtaining a score of 28 or more in severe measurement (FSS) Obtaining informed consent Absence of pregnancy (pregnancy during the study period or decision to become pregnant at the beginning of the study)

Exclusion criteria

Exclusion criteria: The use of antidepressants The use of other medications effective in relieving fatigue (Ritalin, Pemoline, Amantadine)

Design outcomes

Primary

MeasureTime frame
Fatigue score based on the Fatigue Severity Scale (FSS). Timepoint: Measuring the severity of fatigue at the beginning (before the start of the intervention) and 6 weeks after the start of the intervention. Method of measurement: Fatigue severity scale Questionnaire.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAli Jadidi

Arak University of Medical Sciences

farnosh.ansari99@gmail.com+98 86 3417 3501

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026